Neurocrine Biosciences, Inc. (NBIX)
- Previous Close
109.75 - Open
123.00 - Bid 109.87 x 200
- Ask 127.73 x 200
- Day's Range
116.56 - 130.46 - 52 Week Range
84.23 - 157.98 - Volume
5,008,976 - Avg. Volume
1,586,858 - Market Cap (intraday)
11.766B - Beta (5Y Monthly) --
- PE Ratio (TTM)
33.31 - EPS (TTM)
3.57 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 1995
- 1y Target Est
159.44
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
www.neurocrine.com1,800
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: NBIX
View More
Performance Overview: NBIX
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NBIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NBIX
View MoreValuation Measures
Market Cap
11.77B
Enterprise Value
11.27B
Trailing P/E
40.31
Forward P/E
23.92
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.10
Price/Book (mrq)
4.64
Enterprise Value/Revenue
4.67
Enterprise Value/EBITDA
20.15
Financial Highlights
Profitability and Income Statement
Profit Margin
12.68%
Return on Assets (ttm)
8.75%
Return on Equity (ttm)
12.43%
Revenue (ttm)
2.41B
Net Income Avi to Common (ttm)
305.8M
Diluted EPS (ttm)
3.57
Balance Sheet and Cash Flow
Total Cash (mrq)
943.5M
Total Debt/Equity (mrq)
17.65%
Levered Free Cash Flow (ttm)
272.78M
Research Analysis: NBIX
View MoreResearch Reports: NBIX
View MoreRaising target price to $113.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $113.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRaising target price to $107.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $107.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRaising target price to $101.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $101.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetLowering target price to $92.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $92.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target